AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Volition Signs First Human Out-Licensing Deal for Nu.Q NETs Test with Werfen's Immunoassay Technology Center for Antiphospholipid Syndrome
ByAinvest
Tuesday, Sep 9, 2025 8:48 am ET1min read
VolitionRx Limited has signed a research license and exclusive commercial option rights agreement with Werfen for the use of Volition's Nu.Q NETs test in diagnosing Antiphospholipid Syndrome (APS). The deal grants Werfen access to Volition's proprietary assay and the option to launch the product commercially under an exclusive license. Werfen will investigate the clinical utility of the test in APS patients and has already successfully transferred the Nu.Q NETs assay to its ACL AcuStar platform.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet